Dividend Information About CONMED: Everything You Need to Know Before Its Ex-Dividend Date on Sep 15, 2025
Generated by AI AgentAinvest Dividend Digest
Friday, Sep 12, 2025 9:18 am ET1min read
CNMD--
Aime Summary
CONMED (CNMD) has announced a cash dividend of $0.20 per share, set to be distributed on Oct 3, 2025, with an ex-dividend date of Sep 15, 2025. The company declared this dividend on Aug 7, 2025, aligning with its consistent payout pattern. The most recent dividend, issued on Jul 3, 2025, was also $0.20 per share, suggesting a stable dividend policy. Over the past 10 dividends, the average payout has remained at $0.20, indicating the current distribution is in line with historical trends. Investors must purchase the stock before Sep 15, 2025, to be eligible for this dividend, as any shares acquired on or after that date will not qualify for the upcoming payout.
Recent developments surrounding CONMEDCNMD-- highlight a period of strategic and corporate evolution. Recently, the company announced the appointment of Kim Kelderman to its Board of Directors on Sept 8, 2025, marking a significant leadership update. This move is seen as a step to strengthen corporate governance and align with the company’s long-term goals. Over the past week, CONMED also disclosed a material event through its 8-K filing, shedding light on key operational updates that could influence investor perception and stock performance. Since the last update, the company reiterated its commitment to a $0.20 per share dividend on Oct 3, 2025, with the ex-dividend date confirmed as Sep 15, 2025. These announcements, within the five-day window ending on Sep 12, 2025, collectively point to a company in a phase of strategic refinement and financial clarity.
Amid these corporate developments, CONMED’s stock has shown some volatility, with recent trading reflecting a price of $52.81 as of the last trade. However, over the past six months, the stock has declined by approximately 14.7%, underperforming broader market benchmarks such as the S&P 500. Analysts have pointed to this as a potential risk factor for investors, emphasizing the need for caution. Despite these challenges, the company’s recent dividend announcements and board updates suggest a stabilizing effort to bolster investor confidence and reinforce long-term value. With the ex-dividend date approaching on Sep 15, 2025, investors are advised to consider both the financial fundamentals and the recent strategic moves before making decisions. The ex-dividend date is the last day for investors to buy the stock and receive the dividend, with any purchase after that date ineligible for this payout.
CONMED (CNMD) has announced a cash dividend of $0.20 per share, set to be distributed on Oct 3, 2025, with an ex-dividend date of Sep 15, 2025. The company declared this dividend on Aug 7, 2025, aligning with its consistent payout pattern. The most recent dividend, issued on Jul 3, 2025, was also $0.20 per share, suggesting a stable dividend policy. Over the past 10 dividends, the average payout has remained at $0.20, indicating the current distribution is in line with historical trends. Investors must purchase the stock before Sep 15, 2025, to be eligible for this dividend, as any shares acquired on or after that date will not qualify for the upcoming payout.
Recent developments surrounding CONMEDCNMD-- highlight a period of strategic and corporate evolution. Recently, the company announced the appointment of Kim Kelderman to its Board of Directors on Sept 8, 2025, marking a significant leadership update. This move is seen as a step to strengthen corporate governance and align with the company’s long-term goals. Over the past week, CONMED also disclosed a material event through its 8-K filing, shedding light on key operational updates that could influence investor perception and stock performance. Since the last update, the company reiterated its commitment to a $0.20 per share dividend on Oct 3, 2025, with the ex-dividend date confirmed as Sep 15, 2025. These announcements, within the five-day window ending on Sep 12, 2025, collectively point to a company in a phase of strategic refinement and financial clarity.
Amid these corporate developments, CONMED’s stock has shown some volatility, with recent trading reflecting a price of $52.81 as of the last trade. However, over the past six months, the stock has declined by approximately 14.7%, underperforming broader market benchmarks such as the S&P 500. Analysts have pointed to this as a potential risk factor for investors, emphasizing the need for caution. Despite these challenges, the company’s recent dividend announcements and board updates suggest a stabilizing effort to bolster investor confidence and reinforce long-term value. With the ex-dividend date approaching on Sep 15, 2025, investors are advised to consider both the financial fundamentals and the recent strategic moves before making decisions. The ex-dividend date is the last day for investors to buy the stock and receive the dividend, with any purchase after that date ineligible for this payout.

Sip from the stream of US stock dividends. Your income play.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet